Liver damage while Covid-19: problems of pathogenesis and treatment
https://doi.org/10.31146/1682-8658-ecg-187-3-178-185
Abstract
The purpose of the review is to present an analysis of the current literature data on the pathogenesis and therapy of liver damage in Covid-19. Liver damage in COVID-19 patients can be caused by the direct cytopathogenic effect of SARS-CoV-2, an uncontrolled immune response, sepsis, severe hypoxia, or drug damage. In addition, COVID-19 can exacerbate and decompensate previously formed chronic liver diseases with the development of acute liver failure. Physicians should carefully assess the initial state of the liver, and after prescribing therapy, intensify monitoring of its functional state, especially in patients with severe COVID-19. In each clinical case, the doctor needs to establish the possible mechanisms of organ damage in order to select the most optimal patient management tactics, which would take into account all aspects of the COVID-19 course and liver damage. Currently, additional scientific information is required to uncover the features of liver damage during SARS-CoV-2 infection and in the postcovid period. Patients who have undergone COVID-19 need further monitoring to assess the long-term effects of the disease.
About the Authors
E. A. Lyalyukova
FSBEI VO “Omsk State Medical University” of the Ministry of Health
Russian Federation
Russian Federation
I. V. Dolgalev
FSBEI VO “Siberian State Medical University” of the Ministry of Health of Russia
Russian Federation
Russian Federation
E. N. Chernysheva
FSBEI VO “Astrakhan State Medical University” of the Ministry of Health of Russia
Russian Federation
Russian Federation
I. V. Druk
FSBEI VO “Omsk State Medical University” of the Ministry of Health
Russian Federation
Russian Federation
G. M. Konovalova
FSBEI VPO “Maykop State Technological University Medical Institute”
Russian Federation
Russian Federation
A. V. Lyalyukov
FSBEI VO “Sochi State Medical University”
Russian Federation
Russian Federation
References
1. Chau T.N, Lee K.C, Yao H, Tsang T.Y, Chow T.C, Yeung Y. C., Choi K.W, Tso Y.K, Lau T, Lai S.T, Lai C. L. SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology. 2004 Feb; 39(2):302-10.
2. Yeo C., Kaushal S., Yeo D. Enteric involvement of coronaviruses: is faecal-oral transmission of SARS-CoV-2 possible? Lancet Gastroenterol Hepatol. 2020 Apr; 5(4):335-337
3. Chen N., Zhou M., Dong X., Ou J., Gong F., Han Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 2020; 395(10223): 507-513. doi: 10.1016/S0140-6736(20)30211-7.
4. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565-574.
5. Zhang C, Shi L, Wang F.S Liver injury in COVID-19: management and challenges.
6. Lancet Gastroenterol Hepatol. 2020 May; 5(5):428-430.
7. Zahedi, M., et al., Liver Function in Novel Coronavirus Disease (COVID-19): A Systematic Review and MetaAnalysis. medRxiv, 2020: 2020.05.20.20108357. Doi: 10.1101/2020.05.20.20108357
8. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061-1069.
9. Xu Z., Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Patholigical findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med, 2020, vol. 8, pp. 420-22. Doi: 10.1016/S2213-2600(20)30076-X
10. Chen T., Wu D., Chen H., Yan W., Yang D., Chen G. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368: 1091.
11. Tan YJ, Fielding BC, Goh PY, Shen S, Tan TH, Lim SG, Hong W. Overexpression of 7a, a protein specifically encoded by the severe acute respiratory syndrome coronavirus, induces apoptosis via a caspase-dependent pathway. J Virol. 2004 Dec; 78(24):14043-7.
12. Hamming I., Timens W., Bulthuis M. L., Lely A. T., Navis G., van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-637.
13. Zhang W., Du R. H., Li B., Zheng X. S., Yang X. L., Hu B. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020;9(1):386-389.
14. Xiao F., Tang M., Zheng X., Liu Y., Li X., Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020;158(6):1831-1833.e3.
15. Ministerio de Sanidad. Enfermedad por coronavirus, COVID-19. Madrid: Ministerio de Sanidad; 2020 [actualizado 3 Jul 2020] [citado 12 Jul 2020]. Disponible en: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/ITCoronavirus.pdf
16. Cohen J. The immunopathogenesis of sepsis. Nature. 2002;420:885-891. Doi: 10.1038/nature01326
17. Tanaka T., Narazaki M., Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016;8:959-970. Doi: 10.2217/imt-2016-0020.
18. Yin S., Huang M., Li D. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis [Internet]. 2020 doi: 10.1007/s11239-020-02105-8
19. Mei H., Hu Y. Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19. Chin J Hematol. 2020;41:185-191. doi: 10.3760/cma.j.issn.0253-2727.2020.0002
20. Han H., Yang L., Liu R., Liu F., Wu K.-L., Li J. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020;58:1116-1120. doi: 10.1515/cclm-2020-0188
21. Li J., Li R. J., Lv G. Y., Liu H. Q. The mechanisms and strategies to protect from hepatic ischemia-reperfusion injury. Eur. Rev. Med. Pharmacol. Sci. 2015. Vol. 19, no. 11, pp. 2036-2047.
22. Suleyman G, Fadel RA, Malette KM, et al. Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. JAMA Netw Open. 2020;3(6): e2012270. Published 2020 Jun 1. doi:10.1001/jamanetworkopen.2020.12270
23. COVID-19 and the liver D. Jothimani, R. Venugopal, M. F. Abedin, I. Kaliamoorthy, M. Rela. J Hepatol. 2020 Jun 15. doi: 10.1016/j.jhep.2020.06.006 [Epub ahead of print] PMCID: PMC7295524 PMID: 3255366
24. Interim guidelines “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)”, Version 9.approved. Ministry of Health of Russia 10/26/2020. https://static0.minzdrav.gov.ru/system/attachments/attaches/000/052/548/original/%D0%9C%D0%A0_COVID-19_%28v.9%29.pdf?1603730062@@ Временные методические рекомендации «Профилактика, диагностика и лечение новой короновирусной инфекции (COVID-19)», Версия 9. утв. Минздравом России 26.10.2020
25. Instructions for medical use of the drug favipiravir. Vidal handbook. Moscow. 2020.@@ Инструкция по медицинскому применению лекарственного препарата фавипиравир http://www.vidal.ru/drugs/avifavir, Описание препарата в справочнике Видаль.
26. Instructions for the medical use of the drug hydroxychloroquine. Hydroxychloroquine. Vidal handbook. Moscow. 2020.@@ Инструкция по медицинскому применению лекарственного препарата гидроксихлорохин. Описание препарата в справочнике Видаль.
27. Boettler T., Newsome P. N., Mondelli M. U., Matitic M., Cordeo E., Cornberg M. et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep. 2020;2(3):100113. doi:10.1016/j.jhepr.2020.100113
28. Jeong, In-Kyung et al. Diabetes and COVID-19: Global and regional perspectives. Diabetes Research and Clinical Practice, 2020; 166. doi: 10.1016/j.diabres.2020.108303
29. Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15(1):45. doi:10.1186/s12916-017-0806-8
30. Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol. 2019 Mar;70(3):531-544. doi: 10.1016/j.jhep.2018.10.033. Epub 2018 Nov 9. PMID: 30414863
31. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area [published correction appears in JAMA. 2020 May 26;323(20):2098]. JAMA. 2020;323(20):2052-2059. doi:10.1001/jama.2020.6775
32. Fadini G. P., Morieri M. L., Longato E., Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest [Internet] 2020 http://link.springer.com/10.1007/s40618-020-01236-2;
33. Guan W., Liang W., Zhao Y., Liang H., Chen Z., Li Y. Comorbidity and its impact on 1590 patients with covid-19 in China: a nationwide analysis. Eur Respir J. 2020:2000547
34. Suleyman G, Fadel RA, Malette KM, et al. Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. JAMA Netw Open. 2020;3(6): e2012270. Published 2020 Jun 1. doi:10.1001/jamanetworkopen.2020.12270
35. Bramante C, Tignanelli CJ, Dutta N, et al. Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for Covid-19. Preprint. medRxiv. 2020;2020.09.01.20185850. Published 2020 Sep 2. doi:10.1101/2020.09.01.20185850
36. Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol. 2019 Mar;70(3):531-544. doi: 10.1016/j.jhep.2018.10.033. Epub 2018 Nov 9. PMID: 30414863
37. Kwok R, Choi KC, Wong GL, Zhang Y, Chan HL, Luk AO, Shu SS, Chan AW, Yeung MW, Chan JC, Kong AP, Wong VW. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2016;65:1359-68. doi: 10.1136/gutjnl-2015-309265
38. Portincasa P, Krawczyk M, Smyk W, Lammert F, Di Ciaula A. COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics. Eur J Clin Invest. 2020;50(10):13338. doi:10.1111/eci.13338
39. Younossi Z., Anstee Q. M., Marietti M., Hardy T. Et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018; 15: 11-20. Doi: 10.1038/nrgastro.2017.109
40. Ji D, Qin E, Xu J, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol. 2020;73(2):451-453. doi:10.1016/j.jhep.2020.03.044
41. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5:428-430.
42. Kumar R, Semaine W, Johar M, Tyrrell DL, Agrawal B. Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2’-deoxyribose, on wild-type and mutant hepatitis B virus replication. J Med Chem. 2006;49:3693-3700.
43. Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, Law KI, Tang BS, Hon TY, Chan CS, Chan KH, Ng JS, Zheng BJ, Ng WL, Lai RW, Guan Y, Yuen KY HKU/UCH SARS Study Group. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361:1767-1772.
44. Chen Y. W., Yiu C. B., Wong K. Y. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Res. 2020;9:129.
45. Chan J. F., Chan K. H., Kao R. Y., To K. K., Zheng B. J., Li C. P. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect. 2013;67(6):606-616.
46. Kindrachuk J., Ork B., Hart B. J., Mazur S., Holbrook M. R., Frieman M. B. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrobial Agents Chemother. 2015;59(2):1088-1099.
47. Zumla A., Chan J. F., Azhar E. I., Hui D. S., Yuen K. Y. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327-347.
48. D’Antiga L. Coronaviruses and immunosuppressed patients. The facts during the third epidemic. Liver Transpl. 2020;26(6):832-834.
49. Zha L, Li S, Pan L, Tefsen B, Li Y, French N, Chen L, Yang G, Villanueva EV. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020 May; 212(9):416-420.
50. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061-1069.
Review
For citations:
Lyalyukova E.A., Dolgalev I.V., Chernysheva E.N., Druk I.V., Konovalova G.M., Lyalyukov A.V. Liver damage while Covid-19: problems of pathogenesis and treatment. Experimental and Clinical Gastroenterology. 2021;(3):178-185. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-187-3-178-185
Views:
599
Email this article 